naa a22 4500 510763960 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20130401xx s 000 0 eng 10.1007/s12094-012-0908-x doi (NATIONALLICENCE)springer-10.1007/s12094-012-0908-x Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer [Elektronische Daten] [Pedro Villarejo-Campos, David Padilla-Valverde, Raúl Martin, Pablo Menéndez-Sánchez, Teófilo Cubo-Cintas, Jose Bondia-Navarro, Jesús Fernández] Introduction: Angiogenesis and lymphangiogenesis are essential processes for the formation of blood and lymphatic vessels that allow tumour growth and spread. The binding of VEGF and VEGF-C factors with their receptors (VEGFR2, VEGFR3) in endothelial cells triggers signals that regulate these processes. We compared preoperative serum VEGF and VEGF-C levels with samples obtained after completion of surgery and adjuvant treatment in patients with gastric cancer. In addition, we determined the prognostic value and relationship to survival of serum VEGF and VEGF-C levels. Methods: We used a prospective cohort study of 59 gastric cancer patients who underwent surgery. Serum VEGF and VEGF-C were measured by enzyme-linked immunosorbent assay (ELISA) the day before surgery and 6months later, after completion of adjuvant treatment. Results: Serum VEGF values decreased after treatment in patients with resectable tumours (mean±SD) (405.42±298.38 vs. 306.38±212.47pg/ml; p<0.01), poorly differentiated and undifferentiated tumours (G3, G4) (438±339.71 vs. 322.47±210.71pg/ml; p=0.01), locally advanced gastric tumours (T4 stage) (424.27±323.08 vs. 333.62±221.72pg/ml; p=0.03) and tumours with a greater number of involved regional lymph nodes (N3) (442.38±311.52 vs. 337.4±203.64pg/ml; p=0.04). Serum preoperative VEGF values over 761pg/ml were associated with shorter patient survival. The mean overall survival time for patients with serum VEGF levels higher than 761pg/ml was 7±2.99months (95% CI 1.14-12.86) while for patients with serum VEGF levels of less than 761pg/ml was 21.18±2.88 (95% CI 15.54-26.83) The mean disease-specific survival time for patients with serum VEGF levels higher than 761pg/ml was 6.25±2.53months (95% CI 1.29-11.21) while for patients with serum VEGF levels of less than 761pg/ml was 27.57±3.45 (95% CI 20.80-34.35). Multivariate analysis identified preoperative serum VEGF levels as an independent prognostic factor (HR=0.144; p=0.03). Conclusions: Serum VEGF levels decreased after the completion of treatment in patients with resected tumours, suggesting VEGF tracking may be useful in monitoring progression. Preoperative measurement of serum VEGF may help us identify patients with a poor prognosis. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Gastric cancer nationallicence Serum VEGF nationallicence Serum VEGF-C nationallicence Angiogenesis nationallicence Lymphangiogenesis nationallicence Lymph node metastasis nationallicence Survival nationallicence Villarejo-Campos Pedro Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut Padilla-Valverde David Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut Martin Raúl Área de Estadística e Innovación Operativa. Departamento de Matemáticas, Universidad de Castilla-La Mancha, Castilla La Mancha, Spain aut Menéndez-Sánchez Pablo Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut Cubo-Cintas Teófilo Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut Bondia-Navarro Jose Facultad de Medicina, Universidad de Málaga, Málaga, Spain aut Fernández Jesús Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 265-270 1699-048X 15:4<265 2013 15 12094 https://doi.org/10.1007/s12094-012-0908-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0908-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Villarejo-Campos Pedro Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut NATIONALLICENCE 700 1- Padilla-Valverde David Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut NATIONALLICENCE 700 1- Martin Raúl Área de Estadística e Innovación Operativa. Departamento de Matemáticas, Universidad de Castilla-La Mancha, Castilla La Mancha, Spain aut NATIONALLICENCE 700 1- Menéndez-Sánchez Pablo Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut NATIONALLICENCE 700 1- Cubo-Cintas Teófilo Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut NATIONALLICENCE 700 1- Bondia-Navarro Jose Facultad de Medicina, Universidad de Málaga, Málaga, Spain aut NATIONALLICENCE 700 1- Fernández Jesús Hospital Universitario de Ciudad Real, Carretera Piedrabuena, 20/26-A, 13005, Ciudad Real, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 265-270 1699-048X 15:4<265 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer